Previous studies have shown that induction of G1 arrest and apoptosis by ursolic acid is associated with up-regulation of cyclindependent kinase inhibitor (CDKI) protein p21 in multiple types of cancer cells. However, the functional role of p21 induction in G1 cell cycle arrest and apoptosis, and the mechanisms of p21 induction by ursolic acid have not been critically addressed. In the current study, we demonstrated that p21 played a mediator role in G1 cell cycle arrest by ursolic acid, whereas p21-mediated upregulation of Mcl-1 compromised apoptotic effect of ursolic acid. These results suggest that p21 induction plays a dual role in the anti-cancer activity of ursolic acid in terms of cell cycle and apoptosis regulation. p21 induction by ursolic acid was attributed to p53 transcriptional activation. Moreover, we found that ursolic acid was able to inhibit murine double minute-2 protein (MDM2) and T-LAK cell-originated protein kinase (TOPK), the two negative regulator of p53, which in turn contributed to ursolic acid-induced p53 activation. Our findings provided novel insights into understanding of the mechanisms involved in cell cycle arrest and apoptosis induction in response to ursolic acid exposure.
Introduction p21, also known as cyclin-dependent kinase 1, plays an important role in a number of cellular processes including cell cycle regulation, apoptosis, and autophagy. [1] [2] [3] As a cyclin-dependent kinase, p21 can directly bind to and inhibit the activity of cyclin-CDK2, -CDK1, and -CDK4/6 complexes, leading to cycle arrest. 4 In addition, p21 can also regulate cell proliferation through interacting with proliferating cell nuclear antigen (PCNA), a DNA polymerase accessory factor. 5 Apart from its role in cell cycle regulation, p21 is also involved in the regulation of apoptosis. 2, 6 Several studies have shown that p21 induction functions as pro-apoptotic signaling to facilitate apoptosis induction in response to certain apoptotic stimuli. 7, 8 In contrast, several other studies argue that p21 induction may function as pro-survival signaling and antagonize apoptosis induction. 9, 10 Ursolic acid (UA) is a pentacyclic triterpenoid found in apple, rosemary, and holy basil. It has been shown that UA is effective against various types of cancer both in vitro and in vivo. 11, 12 The induction of G1 cell cycle arrest and apoptosis by UA has been suggested to contribute to its anti-cancer activities. [13] [14] [15] [16] Previous studies have shown that induction of G1 arrest and apoptosis by UA is associated with up-regulation of cyclin-dependent kinase inhibitor (CDKI) protein p21Cip1 in multiple types of cancer cells. [13] [14] [15] [16] However, whether p21 induction plays a mediator role in G1 arrest and apoptosis in response to UA exposure has not been addressed. In the current study, we demonstrated for the first time that p21 induction plays a dual role in the anti-cancer activity in terms of cell cycle and apoptosis regulation. Our findings provide evidence for a better understanding of mechanisms underlying cell cycle arrest and apoptosis induction by UA.
Materials and methods

Chemicals and reagents
UA was purchased from Sigma-Aldrich (St. Louis, MO). Antibodies specific for p21, p53, phospho-p53, myeloid cell leukemia-1 (Mcl-1), survivin, Akt, phospho-Akt, TOPK, phospho-TOPK, cleaved poly (ADP-ribose) polymerase (PARP; p89), and b-actin were purchased from Cell Signaling Technology (Beverly, MA). Antibody for cellular Fas-associated death domain-like IL-1 beta-converting enzyme inhibitory protein (c-FLIP) was purchased from Bioworld Technology (Minneapolis, MN). Antibody for MDM2 was purchased from Abcam (Cambridge, UK).
Cell culture and treatments MCF-7 (Michigan Cancer Foundation-7) breast cancer cells were obtained from the American Type Culture Collection. Human colon cancer cells HCT-116 p53 (þ/þ) and p53 (À/À) colon cancer cells were kindly provided by Dr Feng Zhu (Huazhong University of Science and Technology, Wuhan, China). The cells were grown in Dulbecco's Modification of Eagle's Medium (DMEM) supplemented with 10% fetal bovine serum without antibiotics. At 24-48 h after plating when cells were 50-60% confluence, the medium was changed before starting the treatment with UA and/or other agents.
Cell cycle analysis
Cell cycle distribution was measured by flow cytometry analysis of DNA content following staining with propidium iodide (PI). Briefly, the cells were exposed to various concentrations of UA for the time indicated. Seventy-five percent ethanol was used to fix the cells at À20 C overnight. After fixation, the cells were washed with phosphate-buffered saline (PBS) and were resuspended in PBS containing RNAse A (1 mg/mL), and incubated at 37 C for 1 h. The fixed cells were labeled with PI (10 mg/mL) at room temperature in dark. After the labeling, the DNA content was examined by the FACS Calibur flow cytometry using CellQuest Software (Becton Dickinson, Franklin Lakes, NJ).
Apoptosis evaluation
Apoptosis was assessed by two methods. The first was sub-G1 analysis by flow cytometry. The second method was Western blotting analysis of cleaved PARP.
Western blot analysis
The cell lysate was prepared in ice-cold radioimmunoprecipitation assay buffer. Cell lysates were resolved by electrophoresis and transferred to a nitrocellulose membrane. The blot was then probed with primary antibody followed by incubation with the appropriate horseradish peroxidase-conjugated secondary antibodies. The signal was visualized by enhanced chemiluminescence (Pierce, Rockford, IL) and recorded on an X-ray film (Eastman Kodak Company, Rochester, NY).
RNA interference
siRNAs targeting p21 and non-targeting siRNA were purchased from Cell Signaling Technology. siRNAs targeting p53, TOPK, MDM2, and non-targeting siRNA were purchased from Life Technologies. siRNAs targeting Akt and non-targeting siRNA were purchased Santa Cruz Biotechnology. The cells were transfected with 50 or 5 nmol/L of specific or non-targeting siRNA using siPORT TM NeoFX TM Transfection Agent (Ambion, Austin, TX) for 24 h and then were used for subsequent experiments. The knockdown efficiency was validated by Western blotting analysis of the targeting gene expression in three independent experiments.
Statistical analysis
Data are presented as mean AE SD. These data were analyzed with the ANOVA with appropriate post hoc comparison among means. P < 0.05 was considered statistically significant.
Results p21 induction makes a major contribution to UA-induced G1 cell cycle arrest in MCF-7 breast cancer cells
To determine the inhibitory effect of UA on cell growth in MCF-7 breast cancer cells, we measured the changes of cell cycle distribution in response to various concentrations of UA exposure by flow cytometry following staining with PI. As shown in Figure 1 (a), treatment with UA in the concentration range of 10-17.5 mmol/L resulted in significant increase of cell number in G1 phase, whereas the number of cells in G1 phase gradually decreased starting at 20 mmol/ L with onset of apoptosis ( Figure 1b ). To investigate the mechanisms of G1 cell cycle arrest by UA, we examined changes of p21, a key regulator of cell cycle, in response to UA by Western blotting. As shown in Figure 1 (c), UA caused a concentration-dependent up-regulation of p21 that is well correlated with the changes of cell cycle distribution ( Figure  1a ). To critically determine the role of p21 induction in UAinduced G1 cell cycle arrest in MCF-7 breast cancer cells, we tested influences of p21 knockdown on the changes of cell cycle distribution by UA. As shown in Figure 1(d) , under the condition that p21 was silenced by its siRNA, UA-induced G1 cell cycle arrest was nearly abolished, suggesting p21 functions as key mediator in cell cycle arrest induced by UA in MCF-7 breast cancer cells.
p21 induction counteracts apoptotic effect of UA in MCF-7 breast cancer cells
Having found the role of p21 induction in UA-induced G1 cell cycle arrest, we next asked whether p21 induction also played a role in apoptosis induction by UA in MCF-7 breast cancer cells. We measured PARP cleavage and apoptosis induction under the condition that p21 was inactivated by RNAi approach using Western blotting and sub-G1 analysis, respectively. As shown in Figure 2 (a), when p21 was inhibited, treatment with UA for 36 h caused a significantly increased PARP cleavage. Consistent with the increase of PARP cleavage, knockdown of p21 led to a significant increase of apoptosis induction compared with the found in UA/con-si ( Figure 2b) . These results suggest that p21 induction functions as pro-survival signal counteracting apoptotic effect of UA. To decipher the mechanisms underlying the pro-survival function of p21 induction in response to UA, we investigated the role of anti-apoptotic Bcl-2 family protein Mcl-1 in this event since up-regulation of Mcl-1 by p21 has been reported in hyperoxia-induced cell death in H1299 human lung adenocarcinoma cells. 17 As shown in Figure 2 correlated with p21 induction (Figure 1c ). We also measured the effects of UA on expression of survivin and c-FLIP, the two anti-apoptotic proteins. Unlike Mcl-1 induction, no obvious changes of these two proteins were detected in the experimental condition ( Figure 2c ). Furthermore, when p21 was silenced by its siRNA, Mcl-1 induction by UA was dramatically reduced (Figure 2d ). Together, these results suggest that p21 induction compromises apoptotic effect of UA through up-regulation of anti-apoptotic protein Mcl-1 in MCF-7 breast cancer cells.
UA activates p21 through regulation of MDM2/ TOPK-p53 axis p21 is a well-known transcriptional target of p53. 18 To investigate the mechanisms of p21 induction by UA in MCF-7 breast cancer cells, the role of p53 was investigated. We first analyzed changes of p53 in response to UA by Western blotting. As shown in Figure 3 (a), treatment with UA induced a concentration-dependent up-regulation of p53, which is generally consistent with p21 induction.
To determine the role of p53 in UA-induced p21 in MCF-7 cells, we examined the effects of p53 knockdown on p21 expression. As shown in Figure 3 (b), when p53 was inhibited by its siRNA, p21 induction by UA was nearly abolished. Consistent with the changes of p21 expression, p53 inactivation led to a significantly decreased G1 cell cycle arrest in response to UA (Figure 3c ). These results support that p53 activation played a role in UA-induced p21 up-regulation in MCF-7 cells. We further investigated the mechanisms of p53 activation by UA. The expression of MDM2, a major negative regulator of p53, 19 was assessed by Western blotting and results are shown in Figure 3(d) . Treatment with UA caused a concentration-dependent down-regulation of MDM2 expression. It has been shown that Akt can positively regulate MDM2. 20 We next asked whether inhibition of MDM2 by UA was due to suppression of Akt. The phosphorylation status of Akt was examined by Western blotting. As shown in Figure 3(d) , UA induced a concentration-dependent inhibition of Akt phosphorylation which is paralleled with down-regulation of MDM2. Furthermore, inactivation of Akt by RNAi indeed resulted in down-regulation of MDM2 and activation of p53-p21 axis. In addition, we also measured effects of UA on TOPK because it has been shown to regulate p53 activity in certain cell types including MCF-7 breast cancer cells. 21 As shown in Figure 3 (e). UA inhibited TOPK phosphorylation concentration-dependently. Moreover, inhibition of TOPK indeed triggered activation of p53-p21 pathway in MCF-7 cells. To determine the relationship between MDM2 and TOPK inhibition induced by UA, we tested the effect of MDM2 inhibition on TOPK/p-TOPK. As shown in Figure 3 (f), no obvious changes of TOPK/p-TOPK were observed under the condition of MDM2 silencing, indicating suppression of TOPK by UA is not associated with MDM2 inhibition in the present condition. Taken together, these results suggest that p21 induction is attributed to activation of MDM2/TOPK-p53 axis in MCF-7 breast cancer cells. To determine the general application of ursolic-induced p53/p21-mediated G1 cell cycle arrest, we tested the functional role of p53/p21 in cell cycle arrest by UA in HCT-116 p53 (þ/þ) and p53 (À/À) colon cancer cells. We first analyzed the changes of p21 expression in response to UA exposure in these cells. As shown in Figure 4 (a), treatment with UA induced a concentration-dependent up-regulation of p21 in both the p53 wild-type and knockout HCT-116 cells. However, the magnitude of p21 induction in the cells with wild-type p53 is significant stronger than that found in the cells without p53. Consistent with the changes of p21 expression, UA caused a concentration-dependent up-regulation of p53 in p53 wild-type HCT-116 cells. In line with the activation of p53-p21 pathway, UA induced a significant G1 cell cycle arrest in p53 well-type HCT-116 cells, whereas only a slight G1 cell cycle arrest was detected in p53 knockout HCT-116 cells (Figure 4b ). Together, these results suggest that UA induces p53-p21-dependent G1 cell cycle arrest in HCT-116 colon cancer cells which is consistent with that found in MCF-7 breast cancer cells.
Discussion
In the current, we investigated the functional role of p21 induction in cell cycle arrest and apoptosis induction by UA. Our results show that p21 induction plays a paradoxical role in the anti-cancer activity of UA. On the one hand, p21 induction made a major contribution to UA-induced G1 cell cycle arrest. On the other hand, p21 induction compromised UA-apoptotic effect through up-regulation of Bcl-2 anti-apoptotic protein Mcl-1. Our findings provide a novel insight into understanding of the mechanisms of anticancer property of UA. The implication of p21 in apoptosis regulation still remains controversial. Induction of p21 functions either as pro-apoptotic or pro-survival signaling. 2 Our results show that inhibition of p21 induction by RNAi approach led to enhanced PARP cleavage and apoptosis induction by UA, suggesting p21 induction conferring cancer cells resistant to ursolic acid-induced apoptosis, which could compromise anti-cancer activity of UA in terms of apoptosis induction. It has been shown that p21 can exert anti-apoptotic effect through multiple mechanisms including up-regulation of Bcl-2 anti-apoptotic proteins. 17 Our data show that p21 induction was well correlated with up-regulation of antiapoptotic Bcl-2 family protein Mcl-1. Moreover, inactivation of p21 by RNAi approach led to a significant reduction of Mcl-1 expression induced by UA. These results therefore indicate that Mcl-1 is a downstream target of p21 induction to mediate anti-apoptotic signaling against UA-induced apoptotic effect. p21 can be activated by p53-dependent or -independent pathway. 2 To decipher the mechanisms of p21 induction by UA, we examined the effects of p53 knockdown or p53 knockout on p21 expression in MCF-7 and HCT cells, respectively. The results show that knockdown of p53 led to a significant reduced p21 induction by UA in MCF-7 cells. Consistent with the finding in MCF-7 cells, a significant reduced p21 was also observed in p53 knockout HCT-116 cells. In line with the effect of p53 on p21 induction, G1 cell cycle arrest induced by UA was nearly abolished when p53 was inactivated by either knockdown or knockout approaches. These results clearly support involvement of p53-dependent pathway in UA-induced p21 induction.
MDM2 functions as an endogenous inhibitor of p53 to be involved in metabolic regulation of p53 activity through promotion of p53 degradation or p53 nuclear exportation. T-LAK cell-originated protein kinase (TOPK/PBK), a member of serine-threonine mitogen-activated protein kinase kinase family, is found to inhibit p53 activation through directly physical interaction. 21 In the present study, we found that both MDM2 and TOPK were highly expressed in MCF-7 breast cancer cells, which are consistent with previous literatures. [22] [23] [24] [25] Moreover, our results showed that UA induced a dose-dependent p53 activation which was paralleled with inhibition of MDM2 and TOPK. Suppression of either MDM2 or TOPK indeed caused activation of p53/p21 axis in MCF-7 breast cancer cells. Regarding the relationship between MDM2 and TOPK inhibition in our current system, our data demonstrated that inhibition of MDM2 did not affect TOPK/p-TOPK, suggesting they functioned separately rather than connected. These data for the first time demonstrated MDM2 and TOPK as the targets for UA to trigger p53 activation.
In summary, p21 induction plays a pivotal role in UA-induced G1 cell cycle arrest. However, p21 activation by UA counteracts its apoptotic effect through upregulation of Mcl-1. p21 is activated through p53dependent pathway, whereas p53 activation is associated inhibition of MDM2 and TOPK, two negative regulator of p53. Our findings provide evidence for a better understanding of mechanisms underlying cell cycle arrest and apoptosis induction by UA.
